**Author details**

Kazuko Masuo\*

Address all correspondence to: kazuko.masuo@bakeridi.edu.au

Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia

The author declares no conflict of interest.

## **References**

[1] US Department of Health and Human Services. National Institutes of Health Nation‐ al Heart, Lung, and Blood Institute. JNC 7 Express. The Seventh Report of Joint Na‐ tional Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003. http://www.nhlbi.nih.gov/files/docs/guidelines/express.pdf.


MED CTR BOISE on December 24, 2014. http://circ.ahajournals.org/ (Download at VA MED CTR BOISE on December 24 2014).

[15] Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359. doi:10.1001/jama.287.3.356. PMID 11790215.

[2] Ogihara T, Kikuchi K, Matsuoka H, Fujita T, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of

[3] Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult

[4] American Diabetes Association. Standards of medical care in diabetes—2013. Diabe‐

[6] Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, Lanktree MB, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid

[7] Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPI‐

[8] Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J

[9] Park ZH, Juska A, Dyakov D, Patel RV. Statin-associated incident diabetes: a litera‐ ture review. Consul Pharm. 2014; 29: 317-334. doi: 10.4140/TCP.n.2014.317.

[10] Swerdlow DI, Preiss D, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2014

[11] Huskey J, Lindenfeld J, Cook T, Targher G, Kendrick J, Kjekshus J, Pedersen T, Chon‐ chol M. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atheroscle‐

[12] Sheng X, Murphy MJ, MacDonald TM, Wei L. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC

[13] Miyazaki T, Chiuve S, Sacks FM, Ridker PM, Libby P, Aikawa M. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014; 9: e94073. doi: 10.1371/

[14] Stone NJ, Robinson J, et al. Expert panel Members, and ACC/AHA Task Force Mem‐ bers. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. at VA

[5] Carmena R, Betteridge DJ. Statins and diabetes. Semin Vasc Med. 2004; 4: 321-332.

loci. Am J Hum Genet. 2012; 91: 823-838. doi: 10.1016/j.ajhg.2012.08.032.

TER trial. Lancet. 2012; 380: 565-571. doi: 10.1016/S0140-6736(12)61190-8.

Pharmacol Pharmavother. 2014; 5: 181-184. doi: 10.4103/0976-500X.136097.

Sep 24. pii: S0140-6736(14)61183-1. doi: 10.1016/S0140-6736(14)61183-1.

rosis. 2009; 205: 202-206. doi: 10.1016/j.atherosclerosis.2008.11.010.

Public Health. 2012; 12: 712. doi: 10.1186/1471-2458-12-712.

journal.pone.0094073. eCollection 2014.

Hypertension (JSH 2009). Hypertens Res. 2009 Jan;32(1):3-107.

262 Treatment of Type 2 Diabetes

Treatment Panel III) final report. Circulation. 2002; 106: 3143-3121.

tes Care. 2013 Jan;36 Suppl 1:S11-66. doi: 10.2337/dc13-S011


Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256: 2823-2828.


[40] Chapman N, Chang CL, Caulfield M, Dahlöf B, Feder G, Sever PS, Poulter NR. Eth‐ nic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis. 2011; 21: 150-157.

Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial

[27] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin

[28] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J

[29] Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hy‐

[30] hah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation.

[31] Cobain M, Massaro J, Kannel W. General cardiovascular risk profile for use in pri‐

[32] Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications

[33] Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Cir‐

[34] Grundy SM. MedScape Diabetes & Endocrinology. http://www.medscape.com/view‐

[35] Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syn‐

[36] Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, et al. A systemic review and eco‐ nomic evaluation of statins for the prevention of coronary events. Health Technol As‐

[37] Arca M. Ateovastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 2007; 67 Suppl 1: 43-54.

[38] Newman CB, Szarek M, Colhiun HM, Betteridge DJ, et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CASRDS).

[39] Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 201; 32: 2525-2532. doi: 10.1093/eurheartj/

Diab Vasc Dis Res. 2008; 5: 177-183. doi: 10.3132/dvdr.2008.029.

(MRFIT). JAMA. 1986; 256: 2823-2828.

Med. 1998; 339: 1349-1357.

264 Treatment of Type 2 Diabetes

culation. 1997; 95: 1-4.

sess. 2007; 11: 1-160, iii-iv.

article/412684\_2

ehr333.

Survival Study (4S). Lancet. 1994; 344: 1383-1389.

percholesterolemia. N Engl J Med. 1995; 333: 1301-1307.

for therapy. Am J Cardiol. 1995; 75: 45B-52B.

drome. Am J Cardiol. 1998; 81: 18B-25B.

2012; 126: e282-e284. doi: 10.1161/CIRCULATIONAHA.112.122135

mary care: the Framingham Heart Study. Circulation. 2008;117:743–753.


ease treated with atorvastatin (from the treating to new targets study). Am J Cardiol. 2014; 113: 1593-1598. doi: 10.1016/j.amjcard.2014.02.011.


Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insu‐ lin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006; 29:1478-1485.

[59] Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, McLain R, Black DM. Ag‐ gressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-ration‐ ale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000; 86: 250-252.

ease treated with atorvastatin (from the treating to new targets study). Am J Cardiol.

[50] LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, Breazna A; TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010; 105: 283-287. doi: 10.1016/j.amjcard.2009.09.025.

[51] Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwa‐ nia PC, Khush KK. TNT Investigators. Relation of improvement in estimated glomer‐ ular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol. 2012; 109:1761-1766.

[52] Deedwania P, Barter P, Carmena R, Fruchart JC, et al. Treating to New Targets Inves‐ tigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets

[53] Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007;67 Suppl 1:43-54

[54] Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients under‐ going percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Ther‐ apy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009;

[55] Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recur‐ rent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Thera‐ py-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009; 54:

[56] sley WL1; PROVE-IT-TIMI 22. What did PROVE-IT prove?. Diabetes Technol Ther.

[57] Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol. 2010;

[58] Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the

2014; 113: 1593-1598. doi: 10.1016/j.amjcard.2014.02.011.

doi: 10.1016/j.amjcard.2012.02.019.

266 Treatment of Type 2 Diabetes

study. Lancet. 2006 Sep 9;368(9539):919-28.

54: 2290-22955. doi: 10.1016/j.jacc.2009.09.010.

2358-2362. doi: 10.1016/j.jacc.2009.10.005.

106: 354-359. doi: 10.1016/j.amjcard.2010.03.033.

2004 Dec;6(6):864-867.


folk prospective population study. Eur Heart J. 2013; 34: 1350-1357. doi: 10.1093/ eurheartj/eht047.

[80] Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Impact of the JUPITER trial on statin prescribing for primary prevention. Pharmacotherapy. 2014; 34:9-18. doi: 10.1002/phar.1340.

[69] Hawa MI, Buchan AP, Ola T, Wun CC, et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care.

[70] olse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S. Impact of switch‐ ing treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

[71] Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, et al. Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. Stroke. 2014; 45: 2974-82. doi: 10.1161/STROKEAHA.114.005832.

[72] arma A, Cannon CP, de Lemos J, Rouleau JL, et al. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc. 2014; 3: e000784. doi: 10.1161/JAHA.

[73] Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-effectiveness of intensive ator‐ vastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clin Ther. 2008;30 Pt 2:2204-16. doi:

[74] Annemans L, Marbaix S, Webb K, Van Gaal L, Scheen A. Cost effectiveness of atro‐ vastatin in patients in type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atrovastatin diabetes study in the Belgian population. Clin Drug Inves‐

[75] Bener A, Dogan M, Barakat L, Al-Hamag AO. Comparison of cost-effectiveness, safe‐ ty, and efficacy of rosuvastatin versus atrvastatin, pravastatin, and simbastatin in dyslipidemic diabetic patients with or without metabolic syndrome. J Prim Care

[76] Parthan A, Leahy KJ, O'Sullivan AK, Iakoubova OA, et al. Cost effectiveness of tar‐ geted high-atorvastatin therapy following genotype testing in patients with acute coronary syndrome. Pharmacoeconomics. 2013; 31: 519-531. doi: 10.1007/

[77] Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a

[78] Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012; 40: 875-881. doi:

[79] Sondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJ, Wareham NJ, Khaw KT. Clin‐ ical implications of JUPITER in a contemporary European population: the EPIC-Nor‐

Clin Ther. 2014; 36: 58-69. doi: 10.1016/j.clinthera.2013.12.003.

tig. 2010; 30: 133-142. Doi: 10.2165/1153910-000000000-00000.

2014; 37: 1643-1649. doi: 10.2337/dc13-2383.

114.000784.

268 Treatment of Type 2 Diabetes

10.1016/j.clinthera.2008.12.007.

Community Health. 2014; 11: 180-187.

meta-analysis. Clin Ther. 2006; 28: 26-35.

s40273-013-0054-5.

10.1016/j.jacc.2012.07.007.

